Is Selling 52-Week Stock Like Agenus Inc. (AGEN) a Winning Strategy?

July 16, 2018 - By Pearl Odom

Agenus Inc. (NASDAQ:AGEN) Logo

Investors sentiment increased to 1.46 in Q1 2018. Its up 0.20, from 1.26 in 2017Q4. It increased, as 11 investors sold Agenus Inc. shares while 24 reduced holdings. 20 funds opened positions while 31 raised stakes. 46.47 million shares or 27.93% more from 36.32 million shares in 2017Q4 were reported.
Venbio Select Advisor Lc accumulated 704,554 shares or 0.16% of the stock. California Employees Retirement Sys invested in 127,253 shares. Moreover, Victory Mngmt Incorporated has 0% invested in Agenus Inc. (NASDAQ:AGEN) for 3,692 shares. Royal Savings Bank Of Canada, Ontario – Canada-based fund reported 599 shares. Legal & General Grp Inc Pcl reported 13,033 shares or 0% of all its holdings. Citigroup Incorporated owns 0% invested in Agenus Inc. (NASDAQ:AGEN) for 87,090 shares. Washington Bankshares reported 0% of its portfolio in Agenus Inc. (NASDAQ:AGEN). Gsa Prtn Ltd Liability Partnership has invested 0% in Agenus Inc. (NASDAQ:AGEN). Services Automobile Association reported 11,520 shares. Peddock Cap Ltd accumulated 803 shares. State Of Wisconsin Inv Board reported 0% in Agenus Inc. (NASDAQ:AGEN). Voya Investment Mngmt Ltd has invested 0% in Agenus Inc. (NASDAQ:AGEN). 16,631 are held by Bnp Paribas Arbitrage Sa. Alliancebernstein Ltd Partnership stated it has 122,100 shares. 48,619 are held by Amer International Gp.

The stock of Agenus Inc. (NASDAQ:AGEN) hit a new 52-week low and has $1.90 target or 8.00 % below today’s $2.07 share price. The 9 months bearish chart indicates high risk for the $215.28M company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $1.90 price target is reached, the company will be worth $17.22M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.48% or $0.12 during the last trading session, reaching $2.07. About 790,611 shares traded. Agenus Inc. (NASDAQ:AGEN) has declined 0.29% since July 16, 2017 and is downtrending. It has underperformed by 12.86% the S&P500.

Analysts await Agenus Inc. (NASDAQ:AGEN) to report earnings on August, 2. They expect $-0.37 EPS, down 15.63 % or $0.05 from last year’s $-0.32 per share. After $-0.42 actual EPS reported by Agenus Inc. for the previous quarter, Wall Street now forecasts -11.90 % EPS growth.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company has market cap of $215.28 million. The firm offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It currently has negative earnings. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.